Shots:

• The companies collaborated to jointly assess safety and efficacy of Chipscreen's Chidamide in combination with Innovent's Sintilimab + IBI305 in patients with advanced colorectal carcinoma (ACC)
• The focus of the agreement is to explore the combination in clinical applications of immune check-point inhibitor- angiogenesis inhibitor and epigenetic modulator in ACC 
• Chidamide is a HDAC inhibitor inducing apoptosis of tumor cells- has received CFDA’s approval in Dec-2014. Sintilimab (IBI308) & IBI305 (bevacizumab- biosimilar) is an anti-PD-1Ab & an anti VEGF mAb respectively binds to PD-1 receptor & producing anti-tumour targeting tumour cells respectively

Ref: PRNewswire | Image:Innovent